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Abstract
5-androstene-3b,7b,17b-triol (b-AET), an active metabolite of dehydroepiandrosterone (DHEA), reversed glucocorticoid (GC)-
induced suppression of IL-6, IL-8 and osteoprotegerin production by human osteoblast-like MG-63 cells and promoted
osteoblast differentiation of human mesenchymal stem cells (MSCs). In a murine thermal injury model that includes
glucocorticoid-induced osteopenia, b-AET significantly (p,0.05) preserved bone mineral content, restored whole body
bone mineral content and endochondral growth, suggesting reversal of GC-mediated decreases in chondrocyte
proliferation, maturation and osteogenesis in the growth plate. In men and women, levels of b-AET decline with age,
consistent with a role for b-AET relevant to diseases associated with aging. b-AET, related compounds or synthetic
derivatives may be part of effective therapeutic strategies to accelerate tissue regeneration and prevent or treat diseases
associated with aging such as osteoporosis.
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Introduction
Dehydroepiandrosterone (DHEA) and its sulfate are the major
circulating adrenal steroids in humans. Serum levels peak in young
adults, but then steadily decline with age, falling over 80% by age
70. Thus, DHEA is thought to be a good biomarker for aging,
although its biological role remains poorly understood. DHEA
demonstrates a plethora of anti-aging properties in rodents,
including anti-inflammatory [1,2,3], anti-obesity [4], and immune
enhancing [5] activities. In rodents, DHEA opposes certain
activities of endogenous glucocorticoids (GC) such as osteoporosis
[6,7,8], and improves osteoblast growth and bone tissue
morphometry [9]. As the literature grew, DHEA became widely
used as an anti-aging, anti-stress dietary supplement and was
considered a promising agent to treat osteoporosis. Despite
promising results in rodents, DHEA provided only modest
improvement in bone mineral density (BMD) in patients treated
with GC, and elicited unwanted androgenic side effects
[10,11,12,13].
Such widely different outcomes in rodents and humans have
been referred to as ‘the DHEA conundrum’. With respect to bone
preservation in rodents, DHEA was thought to act directly via a
DHEA-specific receptor [9], while this same activity (bone
preservation) appears to require conversion to sex steroids in
humans [14]. Species-specific differences in the adrenal metabo-
lome exist and may play a significant role in the lack of translation
between species. DHEA is abundant in human circulation, but
exogenous DHEA has poor oral bioavailability and is primarily
metabolized into sex steroids, which yield the corresponding side
effects rather than the desired benefits [15,16]. In contrast, DHEA
levels do not existent in rodents [17], and exogenous DHEA is
efficiently converted into highly oxidized metabolites [18]. Rodent
metabolites include a number of androstene and androstane
derivatives that result from additional ring oxidation at carbon 7
and 16 [18,19,20,21,22,23]. Many of the functions initially
attributed to DHEA from observations in rodents are now
thought to be properties of these oxygenated metabolites.
Oxidation via the action of the enzyme CYP7B leads to the 7-
hydroxy derivatives of C-19 steroids [24,25], which are collectively
present in low nanomolar concentrations in human circulation
and are not readily metabolized to potent androgens or estrogens.
Androstene-3b,7b,17b-triol (b-AET) represents a key naturally
occurring 7-hydroxy DHEA metabolite that possesses some of the
anti-inflammatory and GC-opposing activities that have been
attributed to DHEA, but with greater apparent potency
[23,26,27,28]. Loria and colleagues showed that co-culturing
GC-treated Concanavalin A-induced splenocyte with b-AET
antagonized the suppression of IL-2 and IL-3 production and cell
proliferation [29,30]. b-AET was also found to regulate macro-
phage cytokine secretion and to again oppose GC effects [31]. Co-
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LPS-induced TNFa and IL-1b secretion. In rodents, they also
showed that DHEA and b-AET countered the GC-induced
suppression of IL-4 and IgE production, thereby limiting a GC-
induced Th2 shift [32]. These observations suggested that b-AET
has an intrinsic role in the counter regulation of GC.
In the present studies, we probed the GC modulating function
of b-AET in the context of its potential GC counter-regulatory
role in bone biology. We tested if b-AET could effect human bone
marrow derived MSC fate decisions towards the osteoblast lineage
and drive the differentiation and functional activity of human
osteoblast-like MG-63 cells. In rodents, we expanded these studies
using a mouse model of thermal injury that includes an acute
phase GC-induced osteopenia (GIOP) and tested whether b-AET
could spare bone loss in response to thermal injury [33,34,35]. In
humans, we correlated falling plasma levels of b-AET with aging.
Our observations are consistent with a GC- counter regulatory
role for b-AET relevant to bone biology and advancing age.
Treatment with b-AET, related compounds or synthetic deriva-
tives may be part of an effective therapeutic strategy to promote
tissue regeneration, prevent or delay the onset of osteoporosis
associated with trauma or advancing age.
Materials and Methods
Test Article
5-Androstene-3b,7b,17b-triol (b-AET) was produced by Harbor
Biosciences (San Diego, California). In vivo studies used HERF405
vehicle comprised of 0.1% carboxymethylcellulose, 2% polysor-
bate 80 and 0.1% metabisulfite in phosphate-buffered saline,
pH 7.4.
In vitro studies
MG-63 cells. Human sarcoma cell line MG-63 (ATCC:
CRL-1427) was maintained in Minimal Essential Medium (Eagle’s
MEM) supplemented with 0.1 mM non-essential amino acids,
1 mM sodium pyruvate, 2 mM L-glutamine, 100 U/mL
penicillin, 100 mg/mL streptomycin and 10% heat-inactivated
Fetal Bovine Serum (FBS). During experimentation, phenol red-
free MEM medium containing 10% charcoal-dextran adsorbed
FBS was used (assay medium). Typically 0.75610
6 cells were
plated per well in a 6-well plate in 1 mL regular medium for 16-
18 hours. The next morning, fresh assay medium was added along
with b-AET (2 mL in DMSO added to 1 mL). After one hour of
pre-incubation with b-AETa.k.a HE2200; prepared by Harbor
Biosciences), 50 nM dexamethasone (Dex), previously determined
to be approximately IC50 concentration with respect to inhibition
of cytokines) was added (in 2 mL DMSO, final concentration
0.4%). After 7 h later, levels of IL-6, IL-8 or osteoprotegrin (OPG)
were measured in the culture medium using Quantikine ELISA
kits (R & D Systems, Inc., Minneapolis, MN).
Human MSC. Mesenchymal stem cells were derived from
human bone marrow obtained from healthy volunteers (Clonetics,
Inc., San Diego, CA). Bone marrow resident mesenchymal stem
cells (MSCs) were obtained as previously described [36]. The
resulting CD45
2 Glycophorin A
2 cell population was expanded in
culture in the presence of Epidermal Growth Factor and Platelet-
Derived Growth Factor BB (Millipore, Billerica, MA). The
resulting adherent cell population was released with trypsin and
differentiated into the pre-osteoblast population using 10 mM b-
glycerophosphate, 10 nM Dex and 50 nM ascorbic acid
phosphate as previously described [37]. Subcultures derived
from trypsinized adherent cells were supplemented with either 0,
0.1, 1 or 10 mM b-AET and cultured for 15 days. The adherent
population was once again trypsinized and then enumerated by
flow cytometry. The region comprising differentiated mesen-
chymal stem cells including preosteoblast cells was identified using
forward scatter and side scatter characteristics and defined as a
region of interest R1. The average percent of cells expressing the
preosteoblast integrins osteopontin (OP) and osteonectin (ON)
were measured by FACScan analysis by flow cytometry.
Flow cytometry. OP- and ON-specific rabbit anti-human
antibodies were from Calbiochem (San Diego, California). For
flow cytometry, 5610
5 cells were stained according to standard
procedures. Briefly, the cells were incubated with a primary
antibody (10 mg/ml) for 30 min at 4uC. Control cells were
incubated with isotype-matched IgG (Strategic Biosolutions, DE).
After washing with FACS buffer (2%FCS, 0.1% BSA, 0.01%NaN3
in PBS), the cells were incubated with a goat-anti-rabbit FITC-
conjugated secondary antibody (Santa Cruz, CA). Fluorescence
intensity was analyzed on a FACScan (Becton Dickinson, San
Jose, CA) according to standard procedures.
Mouse osteoporosis model
Animals and treatment. Male BALB/c mice (12–14 weeks
old, ,25 g) were obtained from Charles River Labs, Wilmington,
MA. All groups contained 10 animals. Mice were subjected to
20% total body surface area (TBSA) burn by exposing shaved
dorsal skin to a 70uC water bath for seven seconds as described
[35]. b-AET (or vehicle alone) was injected (50 mL) subcutaneously
(sc) at a dose of 0.6 or 1.2 mg/mouse (approximately 25 and
50 mg/kg, respectively) immediately after thermal trauma; a
second dose was administered 48 hours later and then 3 times/
week for 4 weeks. The ‘sham’ group was treated with vehicle
(50 mL) but received no TBSA. Animals used for baseline
measurements received neither TBSA nor any treatment. The
fluorochrome bone marker calcein (Sigma, St. Louis, MO), used
for bone formation measurements, was administered seven and
two days before necropsy as previously described [35]. Animal
housing and experimental manipulations were done at The
University of Utah Radiobiology facilities and were approved by
the Institutional Animal Care and Use Committee.
Bone weights and chemistry. Right femurs of the mice
were cleaned of adherent tissues and stored frozen in moist saline
wrapping. These were later weighed when wet (wet weight), dried
with acetone & ethyl ether and were re- weighed (dry weight). The
dried femurs were then ashed in a muffle furnace (600uC for
12 hours) and weighed (ash weight). The ash to dry weight ratios
are considered an indicator of the amount of inorganic and
organic composition, respectively.
Bone mineral content and density. Bone mineral content
(BMC) and bone mineral density (BMD) were determined by
peripheral dual energy x-ray absorptiometry (DXA) using a
Norland dual x-ray absorptiometer at baseline (two days prior to
thermal trauma) and on the day of necropsy [35]. The scanned
regionsincluded the entire mouse (excluding thetail), thehindlimbs
(femur and tibia) and the lumbar spine. Additionally, the femurs
and tibiae were scanned ex vivo. BMD is expressed as g/cm
2.
BMC is expressed in g.
Bone morphometry and histomorphometry. The left
femur, right and left proximal tibiae, right and left tibio-fibular
junctions and lumbar vertebrae of mice were processed for bone
histomorphometry. The left femur (mid-shaft region) and right and
left tibio-fibular junctions were sawed in cross sections. Right and
left proximal tibiae were sectioned in the frontal plane. The bones
were cut using IsoMetH precision bone saw (Buehler Ltd., Lake
Bluff, IL), and sections were mounted on plastic slides, ground and
polished for histology and histomorphometry. The static
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microscope camera lucida system with a microprocessor and
customized histomorphometry software (KSS Scientific
Consultants, Magna, UT). Additionally, digital images of the
cross-sections were captured and structural data was obtained
using the public domain NIH image analysis software.
Tibio-fibular junction region and the mid-diaphyseal shaft of
the left femur were used for cortical bone histomorphometric
analysis and the secondary spongiosa of the proximal tibial
metaphysis for acquiring the cancellous bone parameters. The
cortical bone static measures included cortical bone area, marrow
area (medullary cavity), average cortical width (from periosteal to
endocortical surface in cross-sections), and minimal cortical width.
The ‘‘dynamic’’ cortical bone growth measurements were
collected using the calcein fluoromarker at the periosteal and
endocortical single- and double-labeled surfaces (% sLS and
%dLS, respectively). Calculated periosteal and endocortical
parameters were mineralizing surface (% MS, which was
calculated as % dLS plus one-half of % sLS), mineral apposition
rate (MAR), and surface- and volume-referent bone formation rate
(sBFR and vBFR, respectively; calculated from % MS and % dLS.
Cortical MAR was not corrected for obliquity. The endocortical
eroded surface, is the surface that has resorption pits (Howship’s
lacunae).The cancellous bone parameters were % bone (percent of
metaphyseal area adjoining to the growth plate), perimeter to area
ratio (is an indicator of trabecular thickness), % sLS, % dLS, %
MS, MAR (corrected for section obliquity by multiplying the
measured rate by p/4), and surface-referent BFR (which is the
BFR [active surface times MAR] normalized to the bone area).
Longitudinal bone growth (endochondral osteogenesis).
Endochondral growth, a function of proliferation and maturation
of the growth plate cartilage, was measured at the proximal tibial
metaphysis of mice and is expressed as growth per day. This was
measured using the fluorochrome bone markers and represents the
growth rate near the end of the study.
Statistical analysis. One-way ANOVA with Tukey’s
multiple comparison (using GraphPad Prism software) was used
for statistical analyses of the in vitro data. Data was plotted as
means 6 SEM, unless indicated otherwise in legends. For mouse
studies, ANOVA with Fisher’s Protected Least Significant
Difference (PLSD) was used, p,0.05 was considered to be
significant.
Human studies
Subjects. Plasma samples were obtained from 252 volunteers
(102 males and 150 females; ages 20–80). Written informed
consent was obtained from all patients as approved by the
institutional review boards (Western IRB, Seattle, WA and RCRC
IRB, Austin TX). Studies were conducted in accordance with the
Declaration of the Helsinki and International Conference on
Harmonisation/WHO Good Clinical Practice standards.
bAET in human subjects. The concentration of b-AET was
measured in plasma by LC-MS/MS. Plasma samples (0.2 mL)
were spiked with D3-b-AET as an internal standard (1 ng/mL),
and steroids were extracted with 10 mL ethyl acetate, and
evaporated under nitrogen. The dried residue was derivatized
with 0.5 mL of 50 mg/mL nicotinyl chloride in anhydrous
pyridine for 1 hour at 80uC, cooled to room temperature, and
quenched with 1 mL 5% sodium bicarbonate. The derivatized
steroids were extracted with 10 mL methyl-tert-butyl ether, dried
under nitrogen, dissolved in HPLC mobile phase, and analyzed by
reverse phase LC-MS/MS. Tri-nicotinyl-b-AET was identified by
its retention time and 622.376 amu transition. A standard curve
from 10–1000 pg/mL in water was used for quantification after
demonstrating equivalence to the method of standard addition.
Statistical Analysis. Data were analyzed using Graphpad
Prism 4 software (Prism, San Diego, CA).
Results
b-AET opposes GC-induced effects on MG-63 osteoblast-
like cell line in vitro
Endogenous GC signaling is essential for osteoblast lineage
commitment, skeletal development, and normal cortical and
cancellous bone volume and architecture [38,39,40,41,42].
However, disregulated levels or pharmacological GC use promotes
osteopenia and has multiple effects on osteoblasts including
decreased proliferation, increased apoptosis, lowered osteoprote-
gerin (OPN), IL-6, IL-8, and osteocalcin (OCN) expression and
elevated 11bhydroxysteroid dehydrogenase-1 (11bHSD-1) expres-
sion, among others [8]. The direct effects of b-AET were explored
on the human osteoblast-like MG-63 cell line. Fifty nanomolar
Dex inhibited the expression of IL-6, IL-8 and OPG, an effect
antagonised by 10 nM b-AET (Figure 1A-C). This amelioration
reached statistical significance (p,0.05) for IL-6 and OPG with a
strong trend (p=0.057) for IL-8.
b -AET promotes differentiation of Human MSC
Mesenchymal stems cells prepared as previously described [36]
and treated with b-AET showed an average of 100–200% increase
in the number of cells bearing the osteopontin (Figure 2) but not
the osteonectin marker (data not shown). There was no dose
response as it appeared as if the lowest dose tested gave the
maximum effect. The mean fluorescence intensity, reflecting the
copy number per cell, was diminished modestly at the lowest
0.1 mM b-AET concentration but neither of the higher doses
tested showed an effect on this parameter (data not shown).
b-AET prevents weight loss in thermal trauma model
Mouse thermal injury models have been used to demonstrate
GC and cytokine associated changes after thermal injury. Skeletal
changes after burn injury have been proposed to be influenced by
a number of factors such as immobilization, aluminum holding
and the production of GC. The precise contribution of these and
other factors to burn induced bone changes remains to be
elucidated [34]. b-AET was tested for effects on bone preservation
in the thermal trauma model by studying various osteogenic and
physiological markers. At the end of the four-week experimental
period, decreased body weight gain was observed in the mice
subjected to thermal trauma compared to sham controls
(2.260.2 g in ‘burn group’ vs. 2.760.2 g in ‘sham’ group,
p,0.05). A similar reduction in net weight gain was observed in
the low dose (25 mg/kg) treatment group while the high dose
group (50 mg/kg) was statistically indistinguishable from sham (1.8
+/2 0.2 and 2.3 +/2 0.3 grams respectively; data not shown).
Lean or fat body mass composition alterations were similar across
all groups and differences were not significant (data not shown).
These observations suggested that effects of thermal stress on
global physiology and growth were minor [35].
b-AET preserves bone mineral content, but not mineral
density, from thermal trauma-induced bone loss
Bone mineral content and weights provide a global indicator of
bone health. The dry weight is a measure of inorganic and organic
content, and ash weight indicates mineral content in the bone. The
ash/dry weight ratios indicate the relative amounts of inorganic
b-AET Slows Bone Loss
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wet and after drying with acetone and also after ashing. As
indicated in Figure 3 (A–C), the wet, dry and ash weights,
respectively, were all decreased by thermal trauma (p,0.05 ‘sham’
vs. vehicle control). These absolute weights were higher in ‘sham’
group compared to baseline as expected from normal growth
during the one-month experimental period (‘baseline’ vs. ‘sham’,
p,0.05). b-AET at the 50 mg/kg dose opposed the thermal
trauma-induced attenuation of normal bone growth and miner-
alization as indicated by wet, dry and ash weights of the femur
bone (p,0.05). Interestingly, the preservation of wet bone weight
in 50 mg/kg group was almost complete (p,0.05 vs. vehicle) and
was indistinguishable from the ‘sham’ group (Fig. 3A). Femur dry
and ash weights were lagging in b-AET-treated groups compared
to the ‘sham’ group, although the 50 mg/kg group was
significantly different than vehicle control (p,0.05; Fig. 3B,C).
While these results suggest a benefit of b-AET treatment on the
organic component of the bone in this model, we did not observe
significant differences in the ash/dry weight ratio between
different groups (data not shown).
We also analyzed bone mineral content (BMC) and determined
bone mineral density (BMD) at various sites. As expected, the bone
mineral content and density decreased globally in thermal trauma
groups (whole body measurement) and at all sites (spine, tibia and
hind-limbs) tested (data not shown). BMD loss was not opposed by
b-AET. However, effects from 25 mg and 50 mg/kg b-AET were
similar and appeared to spare BMC-loss globally (Fig. 3D). In
summary, thermal trauma decreased BMC, wet, dry and ash
weights, and b-AET treatment was able to attenuate this loss.
b-AET limits cortical cancellous bone loss and preserves
endochondral growth rate but not cortical bone loss
The bones of the skeletal system are broadly classified as cortical
or cancellous bones. Long bones, such as femur and tibia, consist
of outer cortical bone that provides mechanical strength and an
inner marrow space. The histomorphometric analysis of the femur
mid-diaphysis region revealed that thermal trauma decreased the
cortical area 2.6% when compared to sham, and the average and
minimum cortical widths by 7.5% and 10% respectively;
accordingly, the marrow space was increased by 6.4% compared
to sham (data not shown). b-AET did not significantly oppose
these changes in cortical bone loss (data not shown). The
tibiofibular junction had a similar result.
In contrast to the long bones, the flat bones (such as ribs or skull)
derive mechanical strength from the trabecular fibers. Trabecular
thickness, number and separation contribute to the overall quality
and strength of cancellous bone. A thicker trabeculae is indicated
by a lower perimeter/area ratio and, thus, increased overall
cancellous bone volume and increased bone strength. The
proximal ends of long bones, unlike the mid-shaft regions, are
also primarily cancellous in nature. The proximal tibial metaphysis
region was analyzed for effects of thermal trauma and b-AET
treatment. Thermal trauma decreased cancellous bone volume by
over 80% (p,0.05, vehicle vs. ‘sham’; Fig. 4A). Similarly, the effect
Figure 1. Effect of b-AET on GC-induced suppression of genes
in MG-63 cell line. MG-63 cells pre-treated (1 h) with b-AET were
exposed to Dex for 8 hours. The expression of IL-6 (A), IL-8 (B) and OPG
(C) was determined by ELISA in the culture medium. Significant
differences from control (0.04% DMSO) are indicated as follows:
***=(p,0.001), **=(p,0.05) and *=(p,0.01). # indicates a significant
difference from Dex (p,0.05). + indicates strong trend (p,0.1). Data are
expressed as means 6 sem; n=3. Absorbance values are plotted for IL-
8 (panel B) because IL-8 concentrations extrapolated from standard
curve in Dex only samples were below the limits of the standard curve
and could not be reliably calculated.
doi:10.1371/journal.pone.0013566.g001
Figure 2. Effect of b-AET on human MSC differentiation.
Mesenchymal stem cells (MSC) derived from human bone were
cultured with b-AET (0, 0.1, 1 or 10 mM) for 15 days. The percentage
of cells expressing the preosteoblast integrins osteopontin (OP) were
measured by flow cytometry. Data are expressed as average % cells +/2
standard deviation.
doi:10.1371/journal.pone.0013566.g002
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region as shown by higher perimeter/area ratios (p,0.05, vehicle
vs. ‘sham’; Fig. 4B). This is consistent with the known sensitivity of
this dynamic to glucocorticoid stress and constant remodeling of
the bone. The b-AET treatment groups increased percent bone
with a strong trend, as well as lowered the perimeter/area ratio,
but without reaching statistical significance (vehicle vs. b-AET
groups). However, these various b-AET effects did culminate into
preservation of the endochondral growth rate as measured at the
tibial epiphyseal growth plate, which was significantly higher in the
50 mg/kg b-AET dose group (p,0.05, vs. vehicle; Fig. 4C). The
observation is consistent with b-AET opposition to GC-induced
suppression of chondrocyte proliferation [43]. Since chondrogen-
esis is responsible for forming a template upon which osteoblasts
deposit bone [44,45], the GC-induced suppression and the
integrity of the proximal tibial epiphyseal growth plate by thermal
trauma may have been alleviated by b-AET.
b-AET reduces endocortical surface bone erosion
To assess osteoclast-mediated bone erosion, we measured
endocortical surface erosion. The thermal trauma increased
erosion by over two-fold at the mid-diaphyseal region of femur
(,6% to 15%, ‘sham vs. ‘vehicle’ control, p,0.05) and b-AET
prevented bone erosion (Figure 4D). This observation is consistent
with attenuation of the glucocorticoid-mediated osteoclast activa-
tion by b-AET.
Levels of b-AET in human plasma decrease with age
The concentration of b-AET in human plasma ranged from 2
to 162 pg/mL in males (Figure 5 Top) and from 6 to 249 pg/mL
in females in our study (Figure 5 Bottom). Levels of b-AET in
human plasma decrease with age. Linear regression analysis
revealed significant non-zero slopes for males (p=0.02; r
2=0.06)
and females (p,0.0001; r
2=0.12). There was no significant
difference in age between males (46.5 +/2 13.6) and females (45.6
+/2 12.5) in our sample, however, females had a significantly
(p=0.0002) higher BMI than males (32.0 +/2 6.4 versus
28.7 +/2 5.6, respectively). Serum levels of DHEA were available
for 75 males and 68 females (data not shown). In these subjects,
serum levels of DHEA also declined with age in both males and
females (p,0.0001 for each; r
2=0.21 and 0.22, respectively). As
reported elsewhere (Auci et al., submitted) serum levels of AET
were highly correlated with serum levels of DHEA in both the
males (p=0.0008; r
2=0.15) and the females (p,0.0001; r
2=0.51).
Serum levels of b-AET were also positively correlated with body
mass index (BMI) and linear regression analysis of b-AET versus
BMI revealed significant non-zero slope for males (p=0.005;
r
2=0.076) and females (p,0.0001; r
2=0.172).
Discussion
We have shown that b-AET reverses GC-induced suppression
of IL-6, IL-8 and OPG expression by human osteoblast-like MG-
63 cells and induced osteoblast differentiation in human bone
Figure 3. Effect of b-AET on femur weights of mice subjected to thermal injury. Male BALB/c mice (n=10 per group) were subjected to 20%
total body surface area and treated (sc injection) with vehicle alone, or with b-AET (25 or 50 mg/kg) immediately after thermal trauma. An identical
treatment was given 48 hours later and then 3 times per week for 4 weeks. Femur was weighed when wet (A), after drying (B) and upon ashing (C).
Panel D indicates whole body BMC. ‘#’, ‘b’ and ‘*’ indicate significant difference from the sham control, baseline and vehicle group, respectively,
p,0.05. The bars represent means 6 SEM.
doi:10.1371/journal.pone.0013566.g003
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treatment blunted the loss of bone mineralization, restored
chondrocyte-mediated endochondral bone growth and slowed
osteoclast-mediated cortical bone erosion. Whole body bone
mineral content, but not density, was restored to normal levels.
Finally, we showed that in men and women, levels of b-AET
decline with age. These observations relevant to the prevention of
osteopenia and may have therapeutic implications for the
treatment of osteoporosis.
Osteoporosis is estimated to already affect 10 million Americans
and almost 34 million more are estimated to have low bone mass,
placing them at increased risk for osteoporosis. Bisphosphonates,
such as Fosamax, which inhibit bone re-absorption, are commonly
prescribed, despite side effects including nausea, abdominal pain,
difficulty swallowing and the risk of an inflamed esophagus or
esophageal ulcers. Although infrequent, serious side effects with
bisphosphonates include osteonecrosis of the jaw, irregular
heartbeats and visual disturbances. The drug inhibits bone-
resorption and has been reported to produce brittle bones that
result in an alarming frequency of spontaneous fractures [46,47].
Selective estrogen receptor modulators (SERMs) such as Ralox-
ifene mimic estrogen’s beneficial effects on bone mineral density in
postmenopausal women without the more serious side effects
associated with estrogen replacement. However, these drugs also
act by inhibiting bone reabsorption. The thyroid hormone
calcitonin, given as a nasal spray, is less often prescribed because
of its low potency compared to the bisphosphonates. Teriparatide
is a powerful analog of parathyroid hormone used to treat
osteoporosis in postmenopausal women and men who are at high
risk of fractures. In contrast to other treatments, teriparatide acts
by stimulating new bone growth. However, it must be given once a
day by injection under the skin on the thigh or abdomen and the
Figure 4. Effect of b-AET on cancellous bone morphometry and histomorphometry and bone resorption and growth. Male BALB/c
mice (n=10 per group) were subjected to 20% total body surface area burn and treated (sc injection) with vehicle alone, or with b-AET (25 or 50 mg/
kg) immediately after thermal trauma. An identical treatment was given 48 hours later and then 3 times per week for 4 weeks. Cancellous bone
morphometry and histomorphometry were measured at the proximal tibial metaphysis of mice (A, B). The endochondral growth rate was measured
at the tibial epiphyseal growth plate (C) Endocortical eroded surface was measured at the surface of the mid-diaphyseal shaft of the femur (D), as an
indicator of osteoclastic bone. ‘#’, ‘b’ and ‘*’ indicate significant differences from the sham control, baseline and vehicle group, respectively, p,0.05.
Data are expressed as means 6 SEM.
doi:10.1371/journal.pone.0013566.g004
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PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13566long-term effects are unknown. Thus, the development of safe,
convenient and cost effective treatment options remain a
significant medical and economic imperative.
The potential role of b-AET in bone formation relevant to the
treatment of osteoporosis may be highlighted by our in vitro
findings related to b-AET –induced OPG expression in Dex-
treated MG-63 osteoblasts. OPG is a soluble decoy RANK
receptor, secreted by osteoblasts, that binds surface RANK ligand
(RANKL) on osteoblasts. This decreases the pool of RANKL
available for RANK receptor binding, decreasing activation of
RANK receptor on pre-osteoclasts and ultimately osteoclast
commitment and differentiation [48]. Since bone formation and
resorption can be uncoupled and are independent processes, the
upregulation of OPG alone might tip the balance towards bone
formation [49]. b-AET also attenuated GC-induced suppression of
IL-6. Although high expression of IL-6 has been proposed to
contribute to bone loss in GIOP, the clinical data is conflicting and
it appears that the up-regulation of soluble IL-6 receptor (sIL-6Ra
and its ratio to soluble gp130 co-receptor governs the effects on
bone during inflammation [50,51,52,53]. Local hyper-production
of IL-8 has been suggested to play a specific role in subchondral
bone loss, since it suppresses osteoblast activity and promotes
osteoclast recruitment [54]. While not reaching statistical signif-
icance in this study, b-AET opposed GC-induced attenuation of
IL-8 signaling.
The present studies are in agreement with recent work of Urban
et al., that also suggested a beneficial effect of -AET on bone
formation. Those studies used the immortalized human fetal
osteoblast cell line hFOB-9 [55] and showed that b-AET
suppressed PPARc activation. PPARc is essential for adipogenesis,
endocrine function of adipose tissue and stem cell fate decisions
that lead to the adipogenic commitment at the expense of the
osteoblastic lineage [56]. The activation of PPARc, as in diabetic
patients managed with the thioglitazones, leads to higher incidence
of bone loss. Conversely, PPARc suppression shifts mesenchymal
stem cell differentiation towards the osteoblastic lineage that
supports bone formation. [56,57,58,59,60,61,62].
Our findings extend observations of Loria and colleagues
[31,63] to cells other than lymphocytes and macrophages and
suggest b-AET attenuates the effects of GC in bone physiology.
Mice that received a 20% TBSA full thickness scald injury
(equivalent to third degree burn) exhibited dramatically increased
bone erosion mediated by high osteoclast activity, IL-6 and GC
levels, that leads to lower cancellous bone formation parameters
4–7 days later [34,35]. Significant short-term osteoclast-mediated
bone surface erosion was prevented by b-AET in a dose-
dependent manner. In a feed-forward mechanism, the endocrine
and cytokine signals initiated by thermal trauma may converge at
the level of the hypothalamic-pitutary-adrenal axis and amplify
both direct and indirect GC effects on the bone. These may
include the disruption of normal osteoimmunological interactions
that involve osteoblasts as well as marrow stromal cells (reviewed
in [64]). Functional GC receptors have been reported on bone
chondrocytes, mononuclear cells and endothelial cells, suggesting
they may also be involved [65]. Even though b-AET protected
BMC, it showed no effect on BMD after one month. Other
factors, besides stress-induced increases in GC contribute to bone
loss in thermally injured mice [34]. Our studies do not prove any
interaction between b-AET and GC signaling and do not rule out
other actions of b-AET relevant to the bone sparing activity we
observed in vivo.
These observations are very similar to the bone loss and
recovery dynamics in severely burned children [64]. The
management of these patients with anabolic agents, recombinant
growth hormone or oxandrolone, a synthetic testosterone
analogue, results in a significant increase in total body or lumbar
spine BMC (T-BMC or LS-BMC, respectively), but no increase in
LS- spine BMD. The increase in BMC but not BMD implies a
proportionate increase in bone area in patients treated with these
anabolic agents. The bones become bigger, even though the
mineralization per unit area, and therefore density, does not differ
between treated and untreated children. Similarly, bisphosphonate
palmidronate given within 10 days of burn significantly protected
BMC starting within 6-8 weeks, but LS-BMD continued a
downward trend over one year and Z-scores (the number of
standard deviations a patient’s BMD differs from the average
BMD of their age, sex, and ethnicity) became significant only at 24
months [66]. The LS-BMD observation is consistent with the
resumption of bone formation only after 9-12 months from the
time of injury. Thus, in order to observe any significant effects on
BMD in the thermal trauma mouse model, a longer follow-up
period would be required.
Figure 5. Correlation of b-AET levels in human plasma with age.
b-AET levels were measured in plasma samples taken from 102 males
(aged 20–80) and 150 females (aged 20–73) by reverse phase LC-MS/
MS. Linear regression analysis revealed significantly non-zero slope for
males (p=0.02; r
2=0.06) and females (p,0.0001; r
2=0.12).
doi:10.1371/journal.pone.0013566.g005
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logical activity is presently unknown. Because b-AET is a DHEA
metabolite, it is important to distinguish potential differences
between the modes of action of these two molecules. Although not
a PPAR ligand, DHEA stimulates PPARc in rodents [67], and
PPAR activation has a number of beneficial effects in rodent
models of inflammation and metabolic disease [68]. In contrast, b-
AET does not stimulate PPAR either in rodents (unpublished
observations) or in humans [69]. A synthetic analog of b-AET,
17a-ethynyl-androst-5-ene-3b,7b,17b-triol (a. k. a. HE3286), has
been reported to elicit rapid non-genomic effects consistent with
activation of a cell membrane receptor [69]. We speculate that b-
AET interacts with the same putative receptor, noting that cell
surface receptors that mediate rapid non-genomic effects have also
been reported for DHEA [70], progesterone, [71] estrogen [72]
and androgen [73]. The ability of b-AET to modulate certain GC
activities may also involve direct or indirect action on steroido-
genic enzymes [74,75] and nuclear transcription factors [76].
Since inflammation itself may exacerbate bone loss[77], a
component of the benefit of b-AET in the thermal injury model
may relate to anti-inflammatory properties [26].
Our finding that levels of b-AET decline with age, in the
context of its role in attenuating certain aspects of GC function,
may have important implications in terms of stem cell biology,
osteoporosis and aging. GCs act to promote the differentiation of
MSC, specifically, but perhaps not exclusively, toward the
adipocyte lineage (for review see [78]). Our results suggest that
the role of b-AET to modify GC activity may extend to stem cells
by perhaps influencing fate decisions [79]. The specific role of b-
AET may require a precise understanding of the niche [80]. Our
finding that plasma levels of b-AET decrease with age make it
tempting to speculate that a reduced b-AET/GC ratio is
associated with an age-related decrease in tissue plasticity as it
relates to stem cell activity and fate decisions. For example, the
case in point, where decreasing levels of b-AET and rising levels of
GC may drive MSC differentiation towards adipocyte formation
at the expense of osteoblastogensis, causing an decreased bone
apposition rate that leads to development of osteoporosis [78].
Whereas native steroid hormones in the C-19 steroid series such
as testosterone appear to require parenteral administration to
effectively observe their pharmacological activity, chemical
modifications have been effective at producing forms for oral
administration. HE3286 is an orally bioavailable analogue of b-
AET that lacks estrogenic or androgenic side effects and has
demonstrated anti-inflammatory, bone sparing properties in
rodents (Harbor Biosciences, unpublished observations). HE3286
was found to be safe and tolerable in early human clinical trials.
This synthetic analogue maybe an effective agent to induce GC
homeostasis and safely, conveniently and cost effectively treat or
prevent diseases of advancing age such as osteoporosis.
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